APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

24 May 2024 10:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street

14 May 2024 08:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

07 May 2024 07:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

01 May 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

26 Apr 2024 07:15:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

23 Apr 2024 07:00:14 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

27 Feb 2024 07:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results

20 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application

26 Jan 2024 07:06:23 By Nasdaq GlobeNewswire

Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues

08 Jan 2024 09:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference

28 Dec 2023 07:00:00 By Nasdaq GlobeNewswire